Comparative Pharmacology
Head-to-head clinical analysis: BICILLIN versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BICILLIN versus KLEBCIL.
BICILLIN vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzathine penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and autolysin inhibition, leading to cell lysis.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
Benzathine penicillin G 1.2 million units intramuscularly once for early syphilis; 2.4 million units intramuscularly weekly for 3 weeks for late latent syphilis.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour (prolonged in renal impairment); clinical context: requires probenecid for extended action
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Primarily renal (60–70% unchanged via glomerular filtration and tubular secretion); minor biliary/fecal elimination (<10%)
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic